Myeloid and lymphoid groups also differed in the expression of mRNAs encoding IL-1, IL-17 and IL-23 pathway components (Fig. 7d), which have been less studied in ALS but can be targeted using biologic therapies now available [122, 123]. The gene discussed is IL17A; the disease is amyotrophic lateral sclerosis.